Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS) -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (527)	12/23/1997 2:06:00 PM
From: William J. Leiby	Read Replies (2) \| Respond to of 849

Hi John: I kinda like to respond but admittedly I don't have a Phd.... I'm aware of Dr Harmon from reading his posts on other threads and he is 1000x better equipped to understand this arena better than I. However, my guess is that manuscripts would be forthcoming. The colorectal NMP is still being evaluated at different sites and once they are completed should we not expect the write-ups? I don't think the co. has ever referred to the CEA as the "gold standard". Albeit, note that the CEA does 100 mil per year. And yes this first submission of the colorectal NMP is for monitoring disease progression and therefore the co's utilization of the 510K. I believe we will see FDA approval for this product. The question for me is whether their new marketing whiz can get the job done. Regards, Bill